Evidence map›Paper›PMID 30607785›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2019

Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.

Ling-Hsiang Chuang, Alexander T Cohen, Giancarlo Agnelli, Pearl D Gumbs, Rupert Bauersachs, Sonja Kroep, Anselm K Gitt, Manuel Monreal, Stefan N Willich, Ben van Hout

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Psychometric properties of the EQ-5D-5L: a systematic review of the literature.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Pooled it
  3. Capturing the late complications of venous thromboembolism.Research and practice in thrombosis and haemostasis · 2026
    Review
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 5 countries.

Ling-Hsiang ChuangPharmerit International, Rotterdam, the Netherlands. lchuang@pharmerit.com.
Alexander T CohenGuy's and St Thomas' NHS Foundation Trust, London, UK.
Giancarlo AgnelliUniversity of Perugia, Perugia, Italy.
Pearl D GumbsDaiichi-Sankyo Europe GmbH, Munich, Germany.
Rupert BauersachsUniversity of Mainz, Mainz, Germany.
Sonja KroepPharmerit International, Rotterdam, the Netherlands.
Anselm K GittHerzzentrum Ludwigshafen, Ludwigshafen, Germany.
Manuel MonrealHospital Universitari Germans Trias I Pujol, Barcelona, Spain.
Stefan N WillichCharité -Universitätsmedizin Berlin, Berlin, Germany.
Ben van HoutUniversity of Sheffield, Sheffield, UK.
Pharmerit (Netherlands) · NLCharité - Universitätsmedizin Berlin · DEDaiichi Sankyo (Germany) · DEGuy's and St Thomas' NHS Foundation Trust · GBHospital Universitari Germans Trias i Pujol · ESJohannes Gutenberg University Mainz · DEKlinikum Ludwigshafen · DEUniversity of Perugia · ITUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is a lack of performance comparisons of the generic quality of life tool EQ-5D-5L against disease- and treatment-specific measures in venous thromboembolism (VTE). The aim of this study was to compare EQ-5D-5L against the pulmonary embolism (PE)-specific PEmb-QoL and the deep vein thrombosis (DVT)-specific VEINES-QOL/Sym, and PACT-Q2 (treatment-specific) questionnaires in five language settings.

methodsPREFER in VTE was a non-interventional disease registry conducted between 2013 and 2014 in primary and secondary care across seven European countries with five languages, including English, French, German, Italian and Spanish. Consecutive patients with acute PE/DVT were enrolled and followed over 12 months. Only patients who completed all three questionnaires at baseline were included in the study sample. The psychometric properties examined included acceptability (missing, ceiling and floor effects), validity (convergent and known-groups validity), and responsiveness. Known groups validity and responsiveness were assessed using both effect size (Cohen's d) and relative efficiency (F-statistic). All analyses were conducted in each language version and the total sample across all languages.

resultsA total of 1054 PE and 1537 DVT patients were included. 14% of PE and 10% of DVT patients had the maximum EQ-5D-5L index score. EQ-5D-5L was low to moderately correlated with other measures (r < 0.5). EQ-5D-5L was associated with larger effect size/relative efficiency in most of known group comparisons in both VTE groups. Similar results were observed for responsiveness. EQ-5D-5L performed relatively better in French, Italian and Spanish language versions.

conclusionOverall EQ-5D-5L is comparable to PEmb-QoL, VEINES-QOL/Sym and PACT-Q2 in terms of acceptability, validity and responsiveness in both PE and DVT populations in English, French, German, Italian and Spanish language version. Nevertheless, it should be noted that each measure is designed to capture different aspects of health-related quality of life.

Indexed as

FemaleHumansMaleMiddle AgedProspective StudiesPsychometricsPulmonary EmbolismQuality of LifeReproducibility of ResultsSurveys and QuestionnairesVenous Thrombosis

Identifiers

PMID30607785
OpenAlexW2907423990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.